Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).
David S. Mathai, Madeleine Cluck, Amna M. Aslam, Erin Amato, Arsalan Azam, Michael Banov, Kathleen A. Barrett, Carl J. Bonnett, David Feifel, Nicolas Grundmann, H. Samuel Ko, Rupert McShane, Sandhya Prashad, Tatiana Santini, Lowan H. Stewart, Patrick Sullivan, Stefany D. Wolfsohn, Jill O. Robinson, Amy L. Mcguire, L. Alison Mcinnes
J Affect Disord May 16, 2026 DOI: 10.1016/j.jad.2026.121970 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Consensus guidelines Peer reviewed |
|---|---|
| Population | Depressive disorders |
| Intervention | Intravenous ketamine infusions |
| Topics | Depression Esketamine Ketamine |
| Citations | 1 |
| Key points | The guidelines establish expert consensus on the use of intravenous ketamine infusions for depressive disorders, covering patient selection, dosing, safety, and treatment protocols. |
Abstract
Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).